Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 20 000 UNITS IN DEXTROSE 5 versus XARELTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 20 000 UNITS IN DEXTROSE 5 versus XARELTO.
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% vs XARELTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin sodium binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin and factor Xa, and to a lesser extent factors IXa, XIa, and XIIa, thereby inhibiting coagulation. It also inhibits platelet aggregation and prolongs clotting times.
Direct factor Xa inhibitor that selectively blocks the active site of factor Xa, inhibiting thrombin generation and thrombus formation.
Adults: Initial IV bolus 80 units/kg, then continuous IV infusion at 18 units/kg/hour. For therapeutic anticoagulation, adjust to target aPTT 1.5-2.5 times control. Dosing per institutional nomogram.
15 mg orally twice daily for 21 days, then 20 mg orally once daily; for atrial fibrillation: 20 mg orally once daily with food; for VTE prophylaxis in hip or knee replacement: 10 mg orally once daily.
None Documented
None Documented
Terminal half-life 1.5 hours (range 1-3 hours) for therapeutic doses; dose-dependent, with higher doses prolonging half-life; half-life prolonged in hepatic or renal impairment.
Terminal elimination half-life: 5–9 hours in young adults, 11–13 hours in elderly (≥65 years). Clinical context: Twice-daily dosing due to relatively short half-life; renal impairment prolongs half-life (up to 15 hours in severe impairment).
Renal: 50-60% as unchanged drug via glomerular filtration; hepatic metabolism (desulfation) accounts for minor clearance; fecal elimination negligible (<1%).
Renal (36% as unchanged drug, 30% as inactive metabolites), fecal/biliary (33% as unchanged drug via hepatobiliary route). Total clearance is 10 L/h.
Category A/B
Category C
Anticoagulant
Anticoagulant